MBX

$0.00

(

+0.00%

)
Quote details

stock

MBX Biosciences, Inc. Common Stock

NASDAQ | MBX

17.51

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$782.97M

Market Cap

-

P/E Ratio

-6.24

EPS

$27.50

52 Week High

$4.80

52 Week Low

HEALTHCARE

Sector

MBX Chart

Recent Chart
Price Action

MBX Technicals

Tags:

MBX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$244K
Total Revenue $0
Cost Of Revenue $244K
Costof Goods And Services Sold $244K
Operating Income -$68M
Selling General And Administrative $11M
Research And Development $57M
Operating Expenses $68M
Investment Income Net -
Net Interest Income $6.3M
Interest Income $6.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $244K
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$68M
Net Income -$62M

Revenue & Profitability

Earnings Performance

MBX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $269M
Total Current Assets $267M
Cash And Cash Equivalents At Carrying Value $49M
Cash And Short Term Investments $49M
Inventory -
Current Net Receivables $682K
Total Non Current Assets $1.2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $213M
Other Current Assets $4.5M
Other Non Current Assets -
Total Liabilities $11M
Total Current Liabilities $11M
Current Accounts Payable $5.3M
Deferred Revenue -
Current Debt -
Short Term Debt $342K
Total Non Current Liabilities $42K
Capital Lease Obligations $171K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $171K
Other Current Liabilities $5.4M
Other Non Current Liabilities $42K
Total Shareholder Equity $257M
Treasury Stock -
Retained Earnings -$138M
Common Stock $5K
Common Stock Shares Outstanding $33M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$55M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $244K
Capital Expenditures $874K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$161M
Cashflow From Financing $234M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$62M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$244K
Total Revenue $0
Cost Of Revenue $244K
Costof Goods And Services Sold $244K
Operating Income -$68M
Selling General And Administrative $11M
Research And Development $57M
Operating Expenses $68M
Investment Income Net -
Net Interest Income $6.3M
Interest Income $6.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $244K
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$68M
Net Income -$62M

MBX News

MBX Profile

MBX Biosciences, Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Carmel, Indiana, specializing in the discovery and development of innovative precision peptide therapies aimed at addressing endocrine and metabolic disorders. Leveraging its proprietary technology platform, MBX is committed to advancing novel therapeutic candidates through rigorous clinical trials. With a focus on unmet medical needs in its targeted therapeutic areas, the company is poised for significant growth and impact in the biopharmaceutical landscape.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.